The Miriam Hospital

lifespan.org

Total trials

182

Active

24

Phase 3

19

Total enrollment

28,317

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 3 of 3 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
EPA1
DHA1
The first FDA-approved LAI ART regimen includes an integrase inhibitor, cabotegravir (CAB), and a non-nucleoside reverse transcriptase inhibitor, rilpivirine (RPV) combined 4 wks1

Next readouts

  • 2025-07-31
  • 2027-08-01

Top conditions

  • Obesity62
  • Overweight and Obesity10
  • HIV10
  • Overweight10
  • Weight Loss9
  • Smoking Cessation6
  • HIV Infections5
  • Pediatric Obesity5

Frequently asked questions about The Miriam Hospital

How many clinical trials does The Miriam Hospital have on ClinicalTrials.gov?
The Miriam Hospital is listed as the lead sponsor on 182 clinical trials in ClinicalTrials.gov, 24 of which are currently active (recruiting, enrolling, or ongoing).
How many of The Miriam Hospital's trials are in Phase 3?
19 of The Miriam Hospital's trials are in Phase 3, spread across 3 active drug programs.
What therapeutic areas does The Miriam Hospital focus on?
The Miriam Hospital's most-studied conditions on ClinicalTrials.gov are Obesity, Overweight and Obesity, HIV, Overweight, Weight Loss.
When are The Miriam Hospital's next clinical trial readouts?
The Miriam Hospital has 2 upcoming primary-completion readouts tracked here; the soonest is “Long-acting Injectable Antiretroviral Treatment to Improve HIV Treatment Among Justice-involved Persons Being Released to the Community”, expected around 2025-07-31.